Revascularization Should Not Be Endpoint For GP IIb/IIIa Inhibitors - Cmte.
Executive Summary
Urgent revascularization should not be included in composite endpoints for active controlled trials of new glycoprotein IIb/IIIa inhibitors, the Cardiovascular & Renal Drugs Advisory Committee agreed Oct. 14.
You may also be interested in...
Roche Is Discussing Lamifiban Submission Based On Troponin T Substudy
Roche is in discussions with regulatory authorities regarding an indication for its intravenous glycoprotein IIb/IIIa platelet aggregation inhibitor lamifiban, based on a prospective substudy of its pivotal Phase III trial.
Roche Is Discussing Lamifiban Submission Based On Troponin T Substudy
Roche is in discussions with regulatory authorities regarding an indication for its intravenous glycoprotein IIb/IIIa platelet aggregation inhibitor lamifiban, based on a prospective substudy of its pivotal Phase III trial.
GP IIb/IIIa Meta-Analysis Would Not Provide Suitable Active Control - Cmte.
A meta-analysis of approved GP IIb/IIIa inhibitors would not provide the best comparator arm for active-control trials of new drugs in the class, FDA's Cardiovascular & Renal Drugs Advisory Committee concluded Oct. 14.